News / Finance
WhisperfromWallStreet.com "Afternoon Gainers AMEX - TAccelr8 Technology Corp.,AXK - Silvercorp Metals Inc,SVM - PharmAthene, Inc,PIP
Accelr8 Technology Corp. - Silvercorp Metals Inc. - PharmAthene, Inc.
Accelr8 Technology Corp.,AXK
-Accelr8 Technology Corporation presented new data at the 109th General Meeting of the American Society for Microbiology (ASM) in Philadelphia. Company scientists and their collaborators from the Washington University in St. Louis School of Medicine (Barnes-Jewish Hospital) reported results for Accelr8’s rapid test for identifying organisms that produce the new "KPC" antibiotic-destroying enzyme. KPC is the first rapidly spreading resistance enzyme to emerge that attacks all members of the largest and most important antibiotic super-family. The family includes a group of drugs known as carbapenems, sometimes called "gorillacillin" by hospital staff because they attack a broad spectrum of otherwise resistant organisms. Because of their importance, physicians prefer to reserve these drugs unless other antibiotics fail.
KPC tends to occur in organisms that are likely to express resistance against most other antibiotic classes. By attacking carbapenems, KPC eliminates a critical fall-back antibiotic class and may render its host bacteria resistant to all but a last-resort antibiotic. KPC emerged recently and spread quickly in North America, then jumped to other continents, and is now spreading into more bacterial species.
---
If you are viewing this press release you are obviously interested in making money in the stock market. In today’s market investors need every tool available. WhisperfromWallStreet.com sends FREE alerts to our subscribers on stocks that we feel are ready to move within hours or days. So far in 2009 we have sent 36 stock alerts to our clients and the average price gain has been 88%. To add additional profits to your portfolio please take a minute and sign up for our free alerts. There is no risk to you and you will see just how accurate we are in our alerts.
Investors sign up for our FREE alerts at www.WhisperfromWallStreet.com
---
Silvercorp Metals Inc,SVM
Silvercorp Metals Inc. is a Canadian-based primary silver producer with mining, development and exploration projects located in the People’s Republic of China. Since commencing production in 2006, Silvercorp has enjoyed high profitability and returns due to the exceptionally high-grade nature of its Ying deposit and the incredibly low-cost jurisdiction in which it operates. The company is publicly traded on the Toronto Stock Exchange in Canada and the NYSE Amex in the U.S. and is a component of the S&P/TSX Composite and Global Mining Indexes.
Silvercorp today is China's largest primary silver producer and has achieved an enviable three-year track record of being the lowest cost producer of silver among its industry peers. In FY2009 (ended March 31, 2009), the company produced a record of 4.2 million ounces of silver at a cash cost of negative $2.77 per ounce. At the same time, the company is growing its resource base through continuous exploration of existing projects as well as acquiring new development projects in multiple jurisdictions. It is also one of only a handful of metals producers to pay shareholders a dividend.
---
PharmAthene, Inc,PIP
PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, today announced that it has submitted a proposal to the Biomedical Advanced Research and Development Authority (BARDA) in response to a Broad Agency Announcement (BAA-BARDA-09-34) for advanced research and development of medical countermeasures for chemical, biological, radiological and nuclear threats. PharmAthene has requested funding to further develop Valortim®, a fully human monoclonal antibody, for the prevention and treatment of anthrax infection. To date, the Company has received funding commitments from the U. S. government totaling up to $24 million to advance the development of Valortim®.
David P. Wright, President and Chief Executive Officer of PharmAthene, commented, "We look forward to BARDA's decision regarding our funding proposal for the advanced development of Valortim®. We believe that Valortim® may have important competitive advantages, including a novel mechanism of action, which, if demonstrated, would make it a strong choice for procurement consideration in the Strategic National Stockpile (SNS). Additional funding will allow us to complete clinical and non-clinical efforts through pivotal safety and efficacy studies, and to perform cGMP and conformance lot manufacturing. If successful, Valortim® may be eligible for acquisition into the SNS for potential use under an Emergency Use Authorization (EUA), and for submission of a Biologics License Application
----
Disclaimer: Full disclaimer at http://whisperfromwallstreet.com/disclaimer.php
WhisperfromWallStreet.com (WFWS) based upon information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by WFWS to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. WFWS is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.whisperfromwallstreet.com or mentioned herein. WFWS may have been compensated with shares or with cash from third party shareholders or the company on behalf of one or more of the companies mentioned in this opinion.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and WFWS undertakes no obligation to update such statements.
This is not a solicitation to buy or sell any securities. WhisperfromWallStreet.com, nor any of its affiliates are not registered investment advisors or a broker dealers. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.
CONTACT: WhisperFromWallStreet.com
